euresist network
play

EuResist Network Present and future Francesca I ncardona I I I - PowerPoint PPT Presentation

EuResist Network Present and future Francesca I ncardona I I I EuResist I nternational meeting Bonn 4 May 2012 The EuResist EU project: 2006-2008 Topics and results Integration of viral genomics with clinical data to predict response to anti


  1. EuResist Network Present and future Francesca I ncardona I I I EuResist I nternational meeting Bonn 4 May 2012

  2. The EuResist EU project: 2006-2008 Topics and results Integration of viral genomics with clinical data to predict response to anti HIV treatment  The EuResist Integrated DataBase (EIDB): the largest existing database of Genotype-response information: more than 33.000 patients  The EuResist Prediction engine: accuracy of 76% Type of Data EuResist Favourable comparison with Patients 33.832 state of the art prediction Therapies 98.421 systems and… CD4 Isolates 455.669 Viral Load Isolates 372.202 with humans: the EVE study Sequences 30.938 III EuResist International meeting Bonn 4 may 2012

  3. The EuResist Network GEI E A European no-profit grouping Founded by Informa, Karolinska Institute, Max Planck Institute, University of Cologne, University of Siena Manages project results and brings them forward Offers partnership to new parties of proved or potential scientific value All partners become members of the EuResist Network Scientific Board The EuResist Network Scientific Board evaluates the scientific adequacy of research proposals that require the access to the data stored in the EuResist Integrated Data Base (EIDB) III EuResist International meeting Bonn 4 may 2012

  4. Partnership with EuResist Network Reasons for partnership include either expanding the EIDB with valuable data or contributing to data analysis in scope with the EuResist Network aims or both. Partner’s activities and data are protected by the data and authorship policies Data provided by a partner always remain the property of the partner. Data providers are included in the list of authors. The priority list of data providers to be included as authors reflects the proportion of contributed cases in the study and credits are accumulated by data providers not included (as in ARCA). III EuResist International meeting Bonn 4 may 2012

  5. Partners InformaPRO Italy Karolinska inst. Sweden Max Planck Germany UniKoeln Germany UniSiena Italy Portugal Irsicaixa Spain Luxembourg KuLeuven Belgium World Friends Kenya MUHAS Tanzania NRL Rwanda Hungary III EuResist International meeting Bonn 4 may 2012

  6. Update of the EI DB structure August 2011 The new schema allows to store: new HIV genes new species such as HCV and HBV New tables allow to store other information such as: infections, diagnoses, type of drugs III EuResist International meeting Bonn 4 may 2012

  7. The EuResist I ntegrated DataBase EI DB III EuResist International meeting Bonn 4 may 2012

  8. Present EI DB coverage PORTUGAL KENYA ITALY III EuResist International meeting Bonn 4 may 2012

  9. EI DB Patients per Centrum Tot 60856 30000 28119 25000 20000 15000 10416 8742 8374 10000 5000 1361 1119 1003 865 657 200 0 Leuven Arevir Arca Karolinska Rwanda Luxemburg Lisbon BI Irsicaixa Tibotec III EuResist International meeting Bonn 4 may 2012

  10. EI DB Standard Datum Tot 9857 5000 4473 4500 4000 3500 3000 2500 2000 1484 1419 1500 1166 1000 436 361 500 228 189 101 0 0 Arevir Leuven Luxembourg Rwanda Arca Karolinska Lisbon Tibotec BI Irsicaixa III EuResist International meeting Bonn 4 may 2012

  11. EI DB Gender Distribution (60.829 patients) Unknown 12% Undifferentiated 0% Female 25% Male 63% III EuResist International meeting Bonn 4 may 2012

  12. EI DB Age Distribution (55.798 patients) 0-13 14-25 1% 2% 26-35 13% 45< 53% 36-45 31% III EuResist International meeting Bonn 4 may 2012

  13. EI DB Ethnic Groups Distribution (58.961 patients) Afro Asian 6% 1% Caucasian 20% Hispanic 1% Other Unknown 0% 72% III EuResist International meeting Bonn 4 may 2012

  14. EI DB Risk Factor Distribution (58.600 patients) Ivda 12% homosexua unknown bisexual 35% 19% heterosexual other 19% 13% vertical blood products transmission 1% 1% III EuResist International meeting Bonn 4 may 2012

  15. EuResist Engine usage May 2011 – Apr 2012 III EuResist International meeting Bonn 4 may 2012

  16. EuResist Network website usage May 2011 – Apr 2012 III EuResist International meeting Bonn 4 may 2012

  17. I ntercontinental activities EDCTP ENNEA project Kenya, Tanzania, Ethiopia PLANTA project Central America SISGENO-EURESIST comparison Brasil Other affiliated projects DOTARV: Vietnam HIVIND: India Eastern promises: Russia (n= 3) III EuResist International meeting Bonn 4 may 2012

  18. Other ongoing activities CHAIN: Collaborative HIV and anti-HIV drug resistance network - EU Research project EUCOHIV project: Collection of Maraviroc treatment cases – sponsored by ViiV Collaboration with Stanford for the realisation of a freely accessible genotype-response repository CETRA project: Collection of Etravirine treatment cases - sponsored by Tibotec EuResist Engine: refinement of prediction error estimate Retraining of EuResist Engine III EuResist International meeting Bonn 4 may 2012

  19. Can we rise prediction accuracy? EuResist Engine trained on 3000 TCE: AUC = 0,76 EuResist Engine trained on 5000 TCE: AUC = 0,80 RDI engine trained on 5.700 TCE: AUC= 0,82 Revell et al AIDS 2011 It seems there is a plateau in accuracy prediction What can we do? EuResist Engine will be trained on new EIDB Take into account human genomics III EuResist International meeting Bonn 4 may 2012

  20. Human genomics: the next step The pattern of Human Leukocyte Antigen (HLA) alleles or supertypes is known to impact HIV disease progression Recent genome-wide association studies (GWAS) done in HIV-positive patients have identified a few single nucleotide polymorphisms (SNPs) partly explaining individual differences in the level of spontaneous control of HIV replication The inter-host network of molecular interactions variability may allow for prediction of anti-HIV therapy outcome and even for personalized treatment Tang 2003, Singh 2008, Tang 2010, Arab-Alameddine 2011, An 2010, Rotger 2010, van Manen 2011, Fellay 2009, Fellay 2010, van Manen 2011 III EuResist International meeting Bonn 4 may 2012

  21. Multilevel virus-host interaction modeling Integrating the host genomics Integrating models at different levels (from molecular to clinical to population level) Integrating machine learning prediction models with biomechanistic description models Collaboration started with DTU, Stanford University, Florida University III EuResist International meeting Bonn 4 may 2012

  22. Objectives for the future To be able to provide treatment support in all countries with relevant HIV infected population To upgrade the prediction system with possibility to predict without genotype (Prosperi et al. PLoSone 2010) To upgrade the prediction system taking into account patient’s immune system To make a HCV EuResist III EuResist International meeting Bonn 4 may 2012

  23. I n the very near future To strenghten the intra-Network communication for: awareness, collaboration, scientific ideas circulation: 3 tele-meetings per year: March, June November To better exploit the EIDB: A person for querying it systematically and propose new studies You are all invited to propose studies on the EIDB! III EuResist International meeting Bonn 4 may 2012

  24. http:/ / w w w .euresist.org http:/ / engine.euresist.org Contact: f.incardona@inform acro.info Thank you III EuResist International meeting Bonn 4 may 2012 24

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend